圓祥生技股份有限公司
今日上漲 2.68%。該股 RSI(6) 為 34.1,處於中性區間,短線無明顯超買超賣訊號。股價站上120日均線,跌破5日、20日、60日均線。KD 指標中性(K=33.1);MACD 柱狀體為負值,空方動能持續。 (自動產生 · 非投資建議)
圓祥生技股份有限公司為專注於抗體藥物研發的新藥開發公司。核心技術包含專有的抗體工程平台,研發多項針對未滿足醫療需求(如癌症、眼科疾病)的新型蛋白質藥物。重點研發管線包含:一、IBI302,治療新生血管性老年黃斑部病變;二、AP505、AP203,針對實體腫瘤之雙特異性抗體。公司透過多樣化的藥物管線與國際夥伴進行授權合作。公司成立於 2013 年,總部位於台灣台北市。
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 11-10 | +28 | 0 | 0 | +28 |
| 11-09 | -28 | 0 | 0 | -28 |
| 11-06 | +74 | 0 | 0 | +74 |
| 11-05 | -15 | 0 | 0 | -15 |
| 11-04 | -100 | 0 | 0 | -100 |
| 11-03 | +110 | 0 | 0 | +110 |
| 11-02 | -67 | 0 | 0 | -67 |
| 10-30 | +86 | 0 | 0 | +86 |
| 10-29 | +38 | 0 | 0 | +38 |
| 10-28 | -48 | 0 | 0 | -48 |
| 10-27 | +15 | 0 | -2 | +13 |
| 10-22 | -3 | 0 | +2 | -1 |
| 10-21 | +1 | 0 | 0 | +1 |
| 10-20 | -3 | 0 | 0 | -3 |
| 10-19 | +31 | 0 | 0 | +31 |
| 10-16 | -42 | 0 | 0 | -42 |
| 10-15 | -32 | 0 | 0 | -32 |
| 10-14 | -31 | 0 | 0 | -31 |
| 10-13 | -2 | 0 | 0 | -2 |
| 10-12 | -38 | 0 | 0 | -38 |
| 10-08 | -241 | 0 | 0 | -241 |
| 10-07 | -115 | 0 | -5 | -120 |
| 10-06 | +14 | 0 | +5 | +20 |
| 10-05 | +13 | 0 | 0 | +13 |
| 10-02 | -54 | 0 | -3 | -57 |
| 10-01 | -16 | 0 | 0 | -16 |
| 09-30 | +16 | 0 | 0 | +16 |
| 09-29 | +3 | 0 | 0 | +3 |
| 09-24 | +16 | 0 | 0 | +16 |
| 09-23 | +8 | 0 | +3 | +11 |
| 09-22 | +44 | 0 | 0 | +44 |
| 09-21 | -106 | 0 | 0 | -106 |
| 09-18 | -36 | 0 | 0 | -36 |
| 09-17 | +360 | 0 | -26 | +334 |
| 09-16 | +63 | 0 | +8 | +71 |
| 09-15 | +255 | 0 | +18 | +273 |
| 09-14 | +10 | 0 | 0 | +10 |
| 09-11 | -26 | 0 | 0 | -26 |
| 09-10 | -6 | 0 | 0 | -6 |
| 09-09 | +1 | 0 | 0 | +1 |
| 09-08 | +10 | 0 | 0 | +10 |
| 09-07 | -25 | 0 | 0 | -25 |
| 09-04 | -3 | 0 | 0 | -3 |
| 09-03 | -19 | 0 | 0 | -19 |
| 09-02 | -65 | 0 | 0 | -65 |
| 09-01 | -193 | 0 | 0 | -193 |
| 08-31 | -120 | 0 | 0 | -120 |
| 08-28 | -71 | 0 | 0 | -71 |
| 08-27 | +268 | 0 | 0 | +268 |
| 08-26 | +47 | 0 | 0 | +47 |
| 08-25 | -4 | 0 | 0 | -4 |
| 08-24 | +53 | 0 | 0 | +53 |
| 08-21 | +23 | 0 | 0 | +23 |
| 08-20 | +42 | 0 | 0 | +42 |
| 08-19 | -33 | 0 | 0 | -33 |
| 08-18 | +16 | 0 | 0 | +16 |
| 08-17 | -7 | 0 | 0 | -7 |
| 08-14 | -233 | 0 | 0 | -233 |
| 08-13 | -44 | 0 | 0 | -44 |
| 08-12 | -258 | 0 | 0 | -258 |
| 08-11 | +363 | 0 | -1 | +362 |
| 08-10 | +313 | 0 | +1 | +314 |
| 08-07 | +6 | 0 | 0 | +6 |
| 08-06 | -43 | 0 | 0 | -43 |
| 08-05 | +15 | 0 | 0 | +15 |
| 08-04 | -6 | 0 | 0 | -6 |
| 08-03 | +12 | 0 | 0 | +12 |
| 07-31 | -42 | 0 | 0 | -42 |
| 07-30 | -9 | 0 | 0 | -9 |
| 07-29 | +52 | 0 | 0 | +52 |
| 07-28 | +36 | 0 | 0 | +36 |
| 07-27 | +24 | 0 | 0 | +24 |
| 07-24 | -6 | 0 | 0 | -6 |
| 07-23 | -61 | 0 | 0 | -61 |
| 07-22 | -7 | 0 | 0 | -7 |
| 07-21 | -78 | 0 | 0 | -78 |
| 07-20 | +50 | 0 | -22 | +28 |
| 07-17 | -59 | 0 | -4 | -63 |
| 07-16 | -53 | 0 | 0 | -53 |
| 07-15 | -44 | 0 | 0 | -44 |
| 07-14 | -4 | 0 | 0 | -4 |
| 07-13 | +49 | 0 | 0 | +49 |
| 07-09 | -62 | 0 | +25 | -37 |
| 07-08 | -250 | 0 | -10 | -260 |
| 07-07 | +269 | 0 | +11 | +280 |
| 07-06 | +80 | 0 | -1 | +79 |
| 07-03 | +77 | 0 | +1 | +78 |
| 07-02 | -12 | 0 | 0 | -12 |
| 07-01 | +4 | 0 | 0 | +4 |
| 06-30 | +39 | 0 | 0 | +39 |
| 06-29 | +72 | 0 | 0 | +72 |
| 06-26 | +10 | 0 | 0 | +10 |
| 06-25 | -94 | 0 | -15 | -109 |
| 06-24 | -3 | 0 | -6 | -9 |
| 06-23 | -12 | 0 | -3 | -15 |
| 06-22 | +61 | 0 | -20 | +41 |
| 06-18 | +144 | 0 | -2 | +142 |
| 06-17 | -177 | 0 | -25 | -202 |
| 06-16 | -87 | 0 | -10 | -97 |
| 06-15 | +201 | 0 | -15 | +186 |
| 06-12 | +88 | 0 | -1 | +87 |
| 06-11 | -61 | 0 | 0 | -61 |
| 06-10 | +71 | 0 | 0 | +71 |
| 06-09 | -54 | 0 | 0 | -54 |
| 06-08 | +68 | 0 | 0 | +68 |
| 06-05 | -274 | 0 | 0 | -274 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/10 | 0 | - | - |
| 2026/09 | 0 | - | - |
| 2026/08 | 0 | - | - |
| 2026/07 | 0 | - | - |
| 2026/06 | 0 | - | - |
| 2026/05 | 0 | - | - |